We are developing first-in-class therapeutics to improve ovarian function and consequently extend female healthspan. We are dedicated to elevating the broader conversation around women’s health, and to building a coalition to drive this vision forward.
Age-related decline in ovarian function leads to adverse health outcomes in women across the board. Oviva aims to extend healthspan in women through developing novel therapeutics that target ovarian function and longevity.
Ovaries show signs of aging decades before other tissues, putting women at a distinct disadvantage.
Loss of ovarian function negatively impacts health, well-being and longevity, leading to adverse health outcomes in women.
The ovarian reserve, which contains all the eggs a woman is born with, is depleted over time. As this finite pool decreases, ovarian function declines, ultimately resulting in menopause.
Women who go through menopause later tend to live longer, as do their male siblings.
And women who enter menopause early tend to have shortened lifespans.
Oviva is addressing the fundamental causal factors of ovarian aging to preserve function and extend healthy lifespan in women.
"Our mission is to identify and develop innovative solutions for fertility patients. The acquisition of Oviva Therapeutics marks a significant milestone in our efforts to bring forward new therapies for those with limited treatment options. In IVF stimulation, OVI-586 offers a biologically grounded approach to improving ovarian response— even in patients with diminished ovarian reserve. We're excited to continue advancing OVI-586 and explore its potential in assisted reproductive technology (ART) and beyond."
.png)
.svg)